UK markets close in 6 hours 58 minutes

OncoCyte Corporation (0KCC.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.5000+0.0100 (+0.40%)
As of 03:10PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 3841.48%
S&P500 52-week change 323.10%
52-week high 34.2256
52-week low 30.0000
50-day moving average 31.7684
200-day moving average 31.7684

Share statistics

Avg vol (3-month) 3382
Avg vol (10-day) 3410
Shares outstanding 540.66M
Implied shares outstanding 6N/A
Float 83.54M
% held by insiders 120.64%
% held by institutions 186.16%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 20.05:1
Last split date 325 Jul 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,610.83%

Management effectiveness

Return on assets (ttm)-15.91%
Return on equity (ttm)-76.26%

Income statement

Revenue (ttm)1.5M
Revenue per share (ttm)0.20
Quarterly revenue growth (yoy)14.60%
Gross profit (ttm)N/A
EBITDA -20.59M
Net income avi to common (ttm)-25.8M
Diluted EPS (ttm)-0.7710
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.43M
Total cash per share (mrq)1.14
Total debt (mrq)2.87M
Total debt/equity (mrq)11.21%
Current ratio (mrq)1.49
Book value per share (mrq)2.48

Cash flow statement

Operating cash flow (ttm)-23.32M
Levered free cash flow (ttm)-6.9M